← Back to home
· Corrected

FDA Investigates Tumor Risk Tied to Zolgensma Gene Therapy

Fact checked by NewsPlainVerified by NewsPlain: confirmed by at least two named sources

Brief

The Food and Drug Administration said on Friday, Nov. 6, that it is investigating a serious risk of tumors, including cancer, in patients given Zolgensma…

Keep reading with NewsPlain Premium

Get the full brief, the full story, what's confirmed, what's still unclear, why it matters, and every source.

3 sources behind this story.

Updates

Correction, : Correction: The approximately $1.1 billion in sales for the first nine months of 2026 covers Novartis’s Zolgensma Group, which includes Itvisma, rather than Zolgensma alone.
About this story

This story includes a public correction.

How NewsPlain works
← Back to home
FDA Investigates Tumor Risk Tied to Zolgensma Gene Therapy — NewsPlain